Researchers from the Cancer Biology & Epigenetics Group at the Research Center of IPO Porto, Portugal have revealed a pivotal link between epigenetic regulation and prostate cancer radioresistance. The study, entitled "Epigenetic Regulation of TP53 is Involved in Prostate Cancer Radioresistance and DNA Damage Response Signaling," was recently published in the prestigious journal Signal Transduction and Targeted Therapy.